Author Archives: Patricia Inacio PhD

Parkinson’s May Impair Perception of Movement in Abstract Art

People with Parkinson’s disease have an altered perception of movement when viewing abstract art as compared with their age- and education-matched healthy peers, a study found. These results suggest that motor responses, aesthetic appreciation, and motion are somehow linked — and that altered neurological function, such as that observed…

#AANAM – Survey Shows More Cannabis Products Used for Pain, Mood

Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. People with Parkinson’s disease are using more cannabis-based products, especially those containing cannabidiol (CBD), as a treatment option to ease…

#AANAM – CLES Led to Sustained Reductions in ‘Off’ Time

Editor’s note: The Parkinson’s News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Carbidopa/levodopa enteral suspension (CLES) provided long-term, sustained, and clinically meaningful reductions in “off” time for people with Parkinson’s disease, according…

Virtual Phase 3 Trial of At-home Light Therapy May Open in Summer 

PhotoPharmics plans to open, possibly this summer, a pivotal Phase 3 clinical trial of its light-based and noninvasive Celeste device in treating Parkinson’s symptoms, for use by patients at home and with trial goals evaluated using telemedicine. A particular company goal for this device, PhotoPharmics also announced, is reaching underserved patients…

Antibody-based Therapies May Trigger Brain Inflammation

New research suggests that brain inflammation is the likely reason antibody-based therapies are ineffective in clinical trials for people with Parkinson’s and Alzheimer’s diseases. The findings show that the binding of the antibody to its target protein — in the case of Parkinson’s disease the misfolded alpha-synuclein —…